M&A
argenx to acquire peptide firm Unnatural Products in deal worth up to $1.15 billion
argenx is buying its research partner of two years for $550 million upfront, gaining an AI-guided platform for discovering macrocyclic peptides. Milestone-linked payments could lift the total to about $1.15 billion. The Santa Cruz team will stay in place as argenx's peptide discovery hub, and closing is targeted for the end of the year.
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.